
NEWSFLASH: Animas Exiting Insulin Pump Market
After nearly two decades, the Johnson & Johnson-owned Animas brand of insulin pumps is shutting down.
In the early morning hours on Thursday (Oct. 5), J&J issued a press release that finalized nine months of speculation on the future of its diabetes insulin pump division. Effective immediately, no more Animas pumps will be sold in the USA or Canada, and it's TBD what will happen to the brand internationally.
Pharma giant J&J has been "strategically evaluating" its three diabetes divisions since January, deciding whether to prop them up financially, sell them off, or shut them down. While many have speculated that an end was near for Animas and possibly even J&J's OneTouch and Lifescan meter brands, nothing has been official until now. The meter brands remain under evaluation, but its pump business is done and J&J has signed an agreement with competitor and market leader Medtronic to take over servicing existing Animas customers.
On the heels of Roche also shutting its insulin pump business in January, what this Animas announcement means is that for the first time since 2002, we PWDs (people with diabetes) in the U.S. will have just three choices of pumps: Medtronic Minimed, Insulet's Omnipod and the Tandem t:slim. Total bummer, given that Animas has been a staple in the industry for 17 years and was well-liked for its waterproof design and Animas Vibe system paired with the Dexcom CGM.
Animas Shutdown: Nuts and Bolts
Here are answers to some of the biggest questions:
How Many? This affects 90,000 existing Animas pump customers, according to the J&J news release (although ot
Continue
reading